Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Ribich

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|April 29, 2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9Matthew H Daniels, Jennifer Castro, Young-Tae Lee, et al.
Communications Biology|April 9, 2025
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitorGordon J Lockbaum, Maureen M Lynes, Sophie A Shen, et al.
Cancer Research|November 26, 2024
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch RepairJennifer Castro, Matthew H Daniels, David Brennan, et al.
Genes & Development|July 3, 2010
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBPAmy K Walker, Fajun Yang, Karen Jiang, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|April 29, 2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9Matthew H Daniels, Jennifer Castro, Young-Tae Lee, et al.
Communications Biology|April 9, 2025
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitorGordon J Lockbaum, Maureen M Lynes, Sophie A Shen, et al.
Cancer Research|November 26, 2024
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch RepairJennifer Castro, Matthew H Daniels, David Brennan, et al.
Genes & Development|July 3, 2010
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBPAmy K Walker, Fajun Yang, Karen Jiang, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Pageof 3